DSpace Fukushima Medical University

福島県立医科大学学術成果リポジトリ = Fukushima Medical University Repository >
福島医学会 = The Fukushima Society of Medical Science >
Fukushima Journal of Medical Science >
Vol.54 (2008) >

このアイテムの引用には次の識別子を使用してください: http://ir.fmu.ac.jp/dspace/handle/123456789/227

このアイテムのファイル:

ファイル 記述 サイズフォーマット
FksmJMedSci_54_p61.pdf1.64 MBAdobe PDFダウンロード
タイトル: Expression of secretoglobin3A2 (SCGB3A2) in primary pulmonary carcinomas
その他のタイトル: SCGB3A2 expression in primary lung cancers
著者: Tachihara-Yoshikawa, Motoko
Ishida, Takashi
Watanabe, Kana
Sugawara, Aya
Kanazawa, Kenya
Kanno, Ryuzo
Suzuki, Toshimitsu
Niimi, Tomoaki
Kimura, Shioko
Munakata, Mitsuru
学内所属: 呼吸器内科学講座
外科学第一講座
病理学第二講座
誌名/書名: Fukushima Journal of Medical Science
巻: 54
号: 2
開始ページ: 61
終了ページ: 72
発行日: 2008年12月
抄録: Secretoglobin (SCGB) 3A2 is a downstream target gene for the thyroid transcription factor-1 (TITF1). SCGB3A2 plays a role as an anti-inflammatory agent, however, its role in primary pulmonary carcinomas has not been examined. We assessed immunohistochemical expression of SCGB3A2 in primary pulmonary carcinomas and evaluated the correlation between the expression and histopathological phenotypes and prognosis. One hundred and fifty-six primary lung cancers undergone for surgical resection were examined. The percentages of SCGB3A2 positive cells were scored and tumors had immunoreactivity in more than 10% of tumor cells were considered positive for SCGB3A2. Overall reactivity for SCGB3A2 was observed in 116 (74.4%) of 156 primary lung cancers. SCGB3A2 was predominantly expressed in adenocarcinomas (86.5%), compared with squamous cell carcinomas (50.0%) and small cell carcinomas (42.9%). The expression in papillary adenocarcinomas was seen at higher frequency than that in tubular adenocarcinomas. There was no significant relationship between SCGB3A2 expression and tumor differentiation, and pathological stage. Positive expression of SCGB3A2 was not associated with better survival rate. SCGB3A2 expression in primary pulmonary carcinomas is high, especially in adenocarcinomas. Our results indicate that SCGB3A2 has a potential to be a specific and useful marker for primary pulmonary adenocarcinomas.
出版者: The Fukushima Society of Medical Science
出版者(異表記): 福島医学会
本文の言語: eng
このページのURI: http://ir.fmu.ac.jp/dspace/handle/123456789/227
本文URL: http://ir.fmu.ac.jp/dspace/bitstream/123456789/227/1/FksmJMedSci_54_p61.pdf
ISSN: 0016-2590
DOI: 10.5387/fms.54.61
PubMed番号: 19418968
関連ページ: https://doi.org/10.5387/fms.54.61
権利情報: © 2008 The Fukushima Society of Medical Science
出現コレクション:Vol.54 (2008)

このアイテムのファイル:

ファイル 記述 サイズフォーマット
FksmJMedSci_54_p61.pdf1.64 MBAdobe PDFダウンロード

このリポジトリに保管されているアイテムは、他に指定されている場合を除き、著作権により保護されています。

 

DSpace Software Copyright © 2002-2006 MIT and Hewlett-Packard